Nivolumab-associated nausea and vomiting as an immune adverse event

Eur J Cancer. 2017 Oct:84:367-369. doi: 10.1016/j.ejca.2017.07.029. Epub 2017 Aug 18.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Humans
  • Immunotherapy / adverse effects
  • Lung Neoplasms / drug therapy*
  • Male
  • Nausea / chemically induced*
  • Nivolumab
  • Vomiting / chemically induced*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Nivolumab